Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8655 |
High Similarity |
NPD6232 |
Discontinued |
0.8613 |
High Similarity |
NPD7473 |
Discontinued |
0.8514 |
High Similarity |
NPD5844 |
Phase 1 |
0.8488 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8471 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8453 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.8427 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8361 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.8353 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8353 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8343 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8305 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8258 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.8258 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8249 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8246 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.8246 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.8239 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8239 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8239 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8239 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8225 |
Intermediate Similarity |
NPD3226 |
Approved |
0.8212 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.8167 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.8111 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.8103 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8092 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8081 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8077 |
Intermediate Similarity |
NPD8312 |
Approved |
0.8077 |
Intermediate Similarity |
NPD8313 |
Approved |
0.8066 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8036 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8022 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.8011 |
Intermediate Similarity |
NPD5494 |
Approved |
0.8 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7989 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7988 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7965 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7941 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7927 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7898 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7882 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7882 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7882 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7882 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7874 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7865 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7865 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7853 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7845 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7841 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7829 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7796 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7784 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7751 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7747 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.774 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7739 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7739 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7738 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7719 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7704 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7704 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7679 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.767 |
Intermediate Similarity |
NPD37 |
Approved |
0.7667 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7665 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7657 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7653 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.7653 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7653 |
Intermediate Similarity |
NPD7698 |
Approved |
0.764 |
Intermediate Similarity |
NPD4965 |
Approved |
0.764 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.764 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7619 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7604 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7604 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7588 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7582 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7566 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7527 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7514 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7513 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7487 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7487 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7475 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7471 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7471 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7471 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7456 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7456 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7443 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7442 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.744 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7432 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7432 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7412 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7411 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.7404 |
Intermediate Similarity |
NPD8155 |
Clinical (unspecified phase) |
0.7401 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7401 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7391 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD920 |
Approved |
0.7386 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7384 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7381 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7371 |
Intermediate Similarity |
NPD6212 |
Phase 3 |
0.7371 |
Intermediate Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.7371 |
Intermediate Similarity |
NPD6213 |
Phase 3 |
0.7363 |
Intermediate Similarity |
NPD919 |
Approved |
0.735 |
Intermediate Similarity |
NPD8319 |
Approved |
0.735 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7341 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.734 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7321 |
Intermediate Similarity |
NPD943 |
Approved |
0.7321 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7314 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD5408 |
Approved |
0.731 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.731 |
Intermediate Similarity |
NPD5404 |
Approved |
0.731 |
Intermediate Similarity |
NPD5405 |
Approved |
0.731 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7302 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7292 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7283 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7273 |
Intermediate Similarity |
NPD8285 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7251 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7241 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7238 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7234 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7209 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7209 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7202 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7176 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7175 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7175 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7151 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7211 |
Clinical (unspecified phase) |
0.7102 |
Intermediate Similarity |
NPD6190 |
Approved |
0.71 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.709 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.7076 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7069 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7062 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7041 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7035 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7024 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7024 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.701 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6995 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6991 |
Remote Similarity |
NPD8059 |
Phase 3 |
0.6991 |
Remote Similarity |
NPD8058 |
Clinical (unspecified phase) |
0.6989 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6982 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6949 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6941 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6919 |
Remote Similarity |
NPD1613 |
Approved |
0.6919 |
Remote Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD4288 |
Approved |
0.691 |
Remote Similarity |
NPD2309 |
Approved |
0.6907 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD1470 |
Approved |
0.6901 |
Remote Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.6901 |
Remote Similarity |
NPD3764 |
Approved |
0.6898 |
Remote Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.6882 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6875 |
Remote Similarity |
NPD7266 |
Discontinued |
0.6875 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6864 |
Remote Similarity |
NPD2798 |
Approved |
0.6857 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6851 |
Remote Similarity |
NPD6273 |
Approved |
0.6827 |
Remote Similarity |
NPD7585 |
Approved |
0.6826 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6825 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6816 |
Remote Similarity |
NPD4360 |
Phase 2 |
0.6816 |
Remote Similarity |
NPD4363 |
Phase 3 |
0.6805
|
Remote Similarity |
NPD1203 |
Approved |